The drug, GR-MD-02, showed no difference from a placebo in nearly all measures to treat nonalcoholic steatohepatitis, or NASH. Galectin derived the drug from fruit pectin.
For more on this story, read TheStreet's Adam Feuerstein's article here.
Must Read: Galectin Drug is a Fatty Liver FlopSTOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. The stock was down 55.91% to $6.41 at 1 p.m. More than 4.4 million shares had changed hands, compared to the average volume of 298,559. GALT data by YCharts STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts